Showing results (1051-1060 of 1,468) with videos related to
Sort By:
Pageof 147
Free Radical Biology & Medicine|May 3, 2008
Protective effects of peroxiredoxin-1 at the injured blood-brain barrierGerty Schreibelt, Jack van Horssen, Reiner F Haseloff, et al.The Lancet. Oncology|October 2, 2013
PET imaging of oestrogen receptors in patients with breast cancerMichel van Kruchten, Elisabeth G E de Vries, Myles Brown, et al.Cancer Treatment Reviews|April 29, 2016
Balancing treatment efficacy, toxicity and complication risk in elderly patients with metastatic renal cell carcinomaR R H van den Brom, S C van Es, A M Leliveld, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2016
Molecular imaging in ovarian cancerA K L Reyners, K E Broekman, A W J M Glaudemans, et al.Advanced Drug Delivery Reviews|January 9, 2020
Sphingolipids in Alzheimer's disease, how can we target them?Simone M Crivelli, Caterina Giovagnoni, Lars Visseren, et al.Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|June 22, 2013
Routine screening for Coxiella burnetii infection during pregnancy: a clustered randomised controlled trial during an outbreak, the Netherlands, 2010J M Munster, A C Leenders, C J Hamilton, et al.Acta Neuropathologica|March 28, 2015
Soluble VCAM-1 impairs human brain endothelial barrier integrity via integrin α-4-transduced outside-in signallingAxel Haarmann, Eva Nowak, Annika Deiß, et al.Cancer Immunology, Immunotherapy : CII|September 10, 2025
Upfront whole blood transcriptional patterns in patients receiving immune checkpoint inhibitors associate with clinical outcomeS Hone Lopez, S Loipfinger, A Bhattacharya, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 3, 2017
Theranostics Using Antibodies and Antibody-Related TherapeuticsKirsten L Moek, Danique Giesen, Iris C Kok, et al.European Journal of Cancer (Oxford, England : 1990)|March 11, 2004
Long-term survivors of ovarian malignancies after cisplatin-based chemotherapy; cardiovascular risk factors and signs of vascular damageF Y F L de Vos, J Nuver, P H B Willemse, et al.Pageof 147